Purchase aims to develop therapies for people living with metabolic diseases.
In a deal that could reach up to $1.075 billion pending completion of development and commercial milestones, Novo Nordisk announced its purchase of Inversago Pharma. As part of the deal, Novo Nordisk will acquire Inversago’s lead development asset INV-202, an oral CB1 inverse agonist. This receptor will be used to continue developing therapies for people living with metabolic diseases such as obesity and diabetes.
“The acquisition of Inversago Pharma will further strengthen our clinical development pipeline in obesity and related disorders,” said Martin Holst Lange, EVP, development, Novo Nordisk, in a company press release. “This promising class of medicine pioneered by the Inversago team could lead to life-changing new treatment options for those living with a serious chronic disease and, in particular, may offer alternative or complementary solutions for people living with obesity.”
Reference: Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases. GlobeNewswire. August 10, 2023. Accessed August 14, 2023. https://www.globenewswire.com/news-release/2023/08/10/2722413/0/en/Novo-Nordisk-to-acquire-Inversago-Pharma-to-develop-new-therapies-for-people-living-with-obesity-diabetes-and-other-serious-metabolic-diseases.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
Trends in Continuing Medical Education
April 12th 2024Elliott Yoo, Senior Media Strategist at epocrates, takes a closer look at the trends in CME consumption and what the future of medical education will be – from the priorities for physicians as they juggle learning with patient care, to what type of activities resonate most with prescribers.